Physician profile
Reagan Michelle Street
NPI 1487845673
$279,774.23
in general payments reported to CMS, 2019-2025
17 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $28K · 2021: $48K · 2022: $51K · 2023: $34K · 2024: $40K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Honoraria: $5,100 · Food and Beverage: $2,629 · Travel and Lodging: $2,470 · Consulting Fee: $2,000 · Education: $67.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,550.00 |
| Honoraria | $5,100.00 |
| Food and Beverage | $2,628.94 |
| Travel and Lodging | $2,469.74 |
| Consulting Fee | $2,000.00 |
| Education | $67.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $209,778.95 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $52,007.30 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17,362.76 | 2020-2024 | Myrisk, Precisetumor |
| Abbvie INC. | $111.09 | 2024-2025 | |
| Intuitive Surgical, INC. | $67.49 | 2019 | |
| Clovis Oncology, INC. | $65.50 | 2019 | |
| Merck Sharp & Dohme LLC | $59.17 | 2019-2025 | Keytruda Qlex |
| Genmab U.S., INC. | $58.02 | 2024-2025 | Tivdak |
| Novartis Pharmaceuticals Corporation | $57.19 | 2024 | |
| Ambu INC. | $44.14 | 2021 | |
| Karyopharm Therapeutics INC. | $33.12 | 2024 | Xpovio |
| Daiichi Sankyo INC. | $29.13 | 2024 | Enhertu |
| Foundation Medicine, INC. | $25.56 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $22.94 | 2020 | |
| Integra Lifesciences Corporation | $22.58 | 2024 | Duraseal Exact Spinal Sealant System, Codman Hakim, Cusa Clarity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.08 | 2022 | |
| Baxter Healthcare | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reagan Street listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.